• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Clozapine for Conduct Disorder in Schizophrenia

Clozapine for Conduct Disorder in Schizophrenia

March 23, 2022
Anne Li, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Anne Li, MD. Dr. Li has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Krakowski M et al, Am J Psychiatry 2021;178(3):266–274

STUDY TYPE: Randomized controlled trial

We often struggle to find effective interventions for aggressive behavior in patients with schizophrenia. For patients with a history of conduct disorder, the task is even more challenging. Patients with schizophrenia will often have shown symptoms of conduct disorder before age 15, although establishing the diagnosis sometimes requires digging in the history since the psychotic disorder may overshadow other symptoms. To make the conduct disorder diagnosis, look for a history of the following during childhood and adolescence: bullying or threatening behaviors, a chronic disregard for rules, criminal activity (eg, stealing, arson, sexual assault, battery), and a lack of empathy or remorse.

In a previous study, the authors demonstrated that clozapine is effective in reducing aggression and impulsive behavior in patients with schizophrenia (Krakowski M et al, Arch Gen Psychiatry 2006;63(6):622–629). But does clozapine also reduce aggression in patients who additionally have a history of conduct disorder?

The authors examined this question by enrolling 99 subjects with schizophrenia in a 12-week double-blind trial conducted in a psychiatric research unit. All subjects had a history of being physically assaultive, and about half (n = 53) had a history of conduct disorder prior to age 15. Subjects were randomly assigned to receive clozapine (n = 33), olanzapine (n = 34), or haloperidol (n = 22), and the frequency and severity of assaults were scored on the Modified Overt Aggression Scale (MOAS). The MOAS total score and the physical assault sub-score were compared across groups.

For all subjects, clozapine was superior to olanzapine and haloperidol in preventing violent behavior, and olanzapine was superior to haloperidol. However, for subjects with a history of conduct disorder, clozapine’s efficacy in preventing violence was particularly high: These subjects were over three times as likely to have a lower MOAS score and four times as likely to have a lower physical assault score compared to subjects on haloperidol. Subjects without a conduct disorder history also benefited from clozapine, but not as dramatically: They were 1.9 times as likely to have a lower MOAS score and 2.7 times as likely to have a lower physical assault score compared to subjects on haloperidol.

CHPR’S Take: For patients with schizophrenia and a history of conduct disorder, clozapine appears significantly more effective in reducing violent behavior compared to olanzapine and haloperidol. Haloperidol seems to be less effective than clozapine or olanzapine for this patient population.
Hospital Psychiatry
KEYWORDS clozapine conduct-disorder schizophrenia violence
Anne Li, MD.

Melatonin vs Memantine for ECT-Related Cognitive Impairment

More from this author
www.thecarlatreport.com
Issue Date: March 23, 2022
SUBSCRIBE NOW
Table Of Contents
Note From the Editor-in-Chief
Sublingual Atropine Drops and Clozapine-Induced Drooling
Clozapine for Conduct Disorder in Schizophrenia
Responding to Sexual Activity on the Inpatient Psychiatric Unit
Management of Psychogenic Polydipsia
Electroconvulsive Therapy: A Primer
Assessing and Treating Catatonia
CME Post-Test - Catatonia, CHPR, April/May/June 2022
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto104192710.jpg
    Hospital Psychiatry

    Management of Depression and Neurocognitive Impairment in Patients With HIV

    Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.